Senses Disorder TRIZ Cases

Disulfide-linked polymeric proteins bind Fc receptors with high avidity, reducing adverse reactions from plasma-derived impurities.

Hyaluronic acid stabilizes prostaglandin analogues, resolving chemical instability and ocular toxicity trade-offs.

Synp198 promoter overcomes low cell-type specificity of viral vectors by combining enhancer and minimal promoter elements for targeted retinal expression.

Linking interfering RNA to a cell penetrating peptide via a polyarginine segment resolves charge neutralization while enabling effective intracellular delivery.

Measure circulating fibrocytes and CXCL12 to guide targeted therapy reducing cell numbers in fibrotic lung disease.

C-terminal steric groups lower IC50 below 1000 nM, enabling effective oral administration of peptides that reduce choroidal neovascularization.

Trifluoromethylpropanamide compounds block HtrA1-mediated extracellular matrix degradation, addressing the lack of dry AMD therapies.

Alpha-1 adrenergic receptor inhibitors treat dry eye syndrome by antagonizing receptors to restore tear production and reduce inflammation.

Amino acid based carbamates cross the blood-brain barrier to modulate sortilin, addressing insufficient central nervous system penetration.

Delivers CFI and cofactors via vectors to treat dry AMD by rebalancing the complement system.

Multi-step chromatography isolates Smilaxchinoside F from rhizome extracts using segmented resin and gel filtration stages.

Cerebrospinal fluid administration delivers AAV vectors to the inner ear, avoiding invasive cochlear injections that damage delicate structures.

Red light activates singlet oxygen to cleave dimeric prodrugs, delivering anti-VEGF agents locally and reducing systemic toxicity in wet AMD treatment.

Azaindole derivatives merge partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition to treat disorders involving both systems.

Small molecule pyrrolo[1,2-a]pyrimidinyl carboxamides replace expensive enzyme therapies to treat Gaucher and Parkinson's diseases with reduced side effects.

Segmented 2,4-pyrimidinediamine compounds inhibit JAK kinases to resolve insufficient therapeutic options for leukemia and lymphoma.

A chimeric protein combines scFv and receptor alpha chain to bind circulating IgE.

A dual VEGF/PDGF antagonist links specific antibodies to inhibit angiogenic pathways.

Ketotifen ophthalmic compositions use hydrogen peroxide stabilizers to protect the active agent from oxidation while maintaining preservative efficacy.

Bicyclic fused heteroaryl compounds inhibit IRAK4 kinase activity, resolving the trade-off between selective inhibition and immunosuppressive side effects.

Novel compounds bind to and modulate the CB2 receptor to treat inflammation and pain.

Compounds with specific molecular structures modulate CFTR activity to improve chloride secretion, addressing defective protein trafficking in cystic fibrosis.

Selective p38 MAP kinase inhibition reduces systemic toxicity while maintaining anti-inflammatory efficacy for asthma and COPD treatment.

Sustained tPA expression via gene therapy maintains chronic intraocular pressure reduction without acute bleeding risks.

Segmented synthesis of crystalline Compound 1 forms modulates CFTR channel opening probability while managing drug manufacturing complexity.

Intrathecal heparan N-sulfatase delivery bypasses the blood-brain barrier using cerebrospinal fluid as an intermediary medium for extensive diffusion.

3',4',5-trimethoxy flavone derivatives stimulate conjunctival mucus secretion, addressing dry eye syndrome root causes without adverse side effects.

Novel protein kinase inhibitor compounds target CHK1 and CHK2 enzymes to block cell proliferation, overcoming cancer drug resistance.

Spirocyclic compounds act as potent thrombin receptor antagonists, addressing limited specificity in current treatments.

Nuc1 peptides bypass tear film clearance and aqueous humor recycling to deliver cargo directly into retinal and corneal cells.

TrkB agonist antibodies activate TrkB receptors to promote retinal ganglion cell survival, addressing glaucoma treatments that fail to reverse neuronal loss.

Position-specific modifications in cyclic RGD peptidomimetics resolve the trade-off between tumor targeting capability and binding specificity.

Formula I compounds activate GPR119 receptors to trigger glucose-dependent insulin secretion, preventing hypoglycemia while maintaining normoglycemia.

Aminoalkylpyrimidine derivatives resolve off-target binding side effects by optimizing substituent groups for selective H4 receptor antagonism.

Dual-action fused ring compounds inhibit thrombin and CB2 receptors to treat thrombosis, atherosclerosis, and inflammatory disorders.

Substituted amide derivatives inhibit Rho kinase to overcome medication resistance in hypertension and cardiovascular disease management.

Fused hexacyclic imidazole derivatives provide novel structural mechanisms to treat inflammatory and autoimmune disorders lacking effective TNFα modulators.

Bispecific antibodies merge IL-17A/F and IL-23p19 binding sites to simultaneously block redundant inflammatory pathways.

Targeting Olfml-3 with monoclonal antibodies overcomes VEGF therapy limitations in diverse tumor types.

Modular ASK1 inhibitor scaffolds resolve the contradiction between potent enzyme inhibition and complex molecular design for treating inflammatory diseases.

AAV vector delivers soluble CD59 gene to retinal cells, reducing membrane attack complex deposition and slowing geographic atrophy progression.

Adipose tissue-derived stromal stem cell compositions treat Crohn's fistulae by delivering at least 30 million cells to resolve recurrence and reinfection.

7-aza-indazole compounds modulate protein kinase activity to target cancer cells, reducing side effects from non-selective chemotherapy.

Specific nucleic acids bind SDF-1 to resolve the lack of targeted antagonists for treating inflammatory diseases.

A small-molecular-weight compound induces NXF expression to potentiate neurotrophic factor activity.

Monoclonal antibodies bind complement C5 to inhibit membrane attack complex assembly without blocking C5a generation.

A biodegradable polymer matrix releases prostacyclin compounds through ester bond hydrolysis to maintain steady drug concentrations.

Combining Protein E and Pilin A into fusion proteins overcomes non-typeable Haemophilus influenzae adhesion to prevent otitis media.